1 citations
,
July 2023 in “Pharmaceutics” New microneedles deliver drugs through the skin accurately and effectively.
49 citations
,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
3 citations
,
March 1981 in “Journal of Toxicology and Environmental Health” Rats developed lung issues from the drugs, but these cleared quickly after stopping them.
3 citations
,
July 2025 in “International Immunopharmacology”
4 citations
,
August 2001 in “Epilepsia” Treating epilepsy is complex, requiring careful drug choice and patient adherence to manage seizures and side effects.
3 citations
,
November 2021 in “Frontiers in medicine” Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
24 citations
,
August 2009 in “Expert opinion on pharmacotherapy” The combination of calcipotriene and betamethasone is more effective and has fewer side effects for treating psoriasis.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
September 2022 in “Journal of Ayub Medical College Abbottabad” Steroid injections are more effective than platelet rich plasma for treating patchy hair loss.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
19 citations
,
January 2009 in “OpenSIUC (Southern Illinois University Carbondale)” Calotropis gigantea and Tridax procumbens extracts reduce inflammation more effectively than low-dose Ibuprofen.
January 2024 in “Acta dermato-venereologica” December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
November 2008 in “British Journal of Hospital Medicine” Non-drug methods effectively managed agitation in a patient with a heart device, leading to improved mental function.
1 citations
,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.